Compare ATOM & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | NERV |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 166.4M |
| IPO Year | 2016 | 2014 |
| Metric | ATOM | NERV |
|---|---|---|
| Price | $3.08 | $2.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.33 |
| AVG Volume (30 Days) | ★ 421.7K | 135.5K |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.41 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $62,000.00 | ★ $41,175,600.00 |
| Revenue This Year | $361.54 | N/A |
| Revenue Next Year | $233.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $2.31 |
| 52 Week High | $12.37 | $12.46 |
| Indicator | ATOM | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 24.32 | 22.50 |
| Support Level | $2.26 | N/A |
| Resistance Level | $3.51 | $5.69 |
| Average True Range (ATR) | 0.23 | 0.25 |
| MACD | -0.11 | -0.07 |
| Stochastic Oscillator | 2.13 | 6.25 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.